EMA validates Pfizer and OPKO’s somatrogon marketing application for review

EMA validates Pfizer and OPKO’s somatrogon marketing application for review

Source: 
Pharmaceutical Business Review
snippet: 

The European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for Pfizer and OPKO’s somatrogon, for review.

Somatrogon is a long-acting human growth hormone (hGH) molecule, which is intended to be injected once-weekly for the treatment of paediatric patients with growth hormone deficiency (GHD).